Anticancer agent 299
Anticancer agent 299 (compound P12) is a cell-cycle inhibitor, senescence inducer, apoptosis inducer, and antiproliferative agent. Anticancer agent 299 exhibits selective activity against cancer cells with minimal effects on non-tumoral chondrocyte cells at relevant concentrations. Anticancer agent 299 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma.
For research use only. We do not sell to patients.
- CAS No.: 1414873-26-9
- Formula: C25H20F3N3O
- Molecular Weight:435.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Anticancer agent 299 (P12) (5-50 μM; 7 days) reduces colony-forming capacity in MCF7 and A375 cells with IC50 values of 30.22 μM and 2.915 μM, respectively, and has minimal effect on non-tumoral TC28a2 cells at 5-35 μM[1].
Anticancer agent 299 (P12) (5 μM; 12 days MCF7 treatment, 4 days A375 measurement) reduces spheroid area in MCF7 cells after 8 and 12 days and in A375 cells after 4 days[1].
Anticancer agent 299 (P12) (5 μM; 7days) reduces the proportion of G2/M phase cells in MCF7 (to 15.65%) and A375 (to 1.94%) cells[1].
Anticancer agent 299 (P12) (5 μM; 7 days) upregulates G1/S and S-phase entry genes in MCF7 cells and downregulates those genes in A375 cells[1].
Anticancer agent 299 (P12) (5 μM; 7 days) increases the expression of senescence-associated genes (p21, p53, IGFBP3, GDF15) in MCF7 and A375 cells[1].
Anticancer agent 299 (P12) (5 μM; 7 days) upregulates SASP factors (IL-6, IL-8) in MCF7 cells but not in A375 cells[1].
Anticancer agent 299 (P12) (≥4 days) increases early apoptosis in MCF7 and A375 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF7, A375, TC28a2
-
Concentration:5, 20, 35, 50 μM (MCF7, A375 colony formation); 5, 20, 35, 50 μM (TC28a2 viability assay)
-
Incubation Time:7 days
-
Result:Significantly reduced the colony-forming capacity of MCF7 and A375 cells in a dose-dependent manner. Achieved an IC50 of 30.22 μM in MCF7 cells and 2.915 μM in A375 cells. Did not produce a significant reduction in the number of adherent viable cells in non-tumoral TC28a2 cells from 5 to 35 μM.
-
Cell Line:MCF7, A375
-
Concentration:5 μM
-
Incubation Time:12 days (MCF7 treatment); 4 days (A375 measurement)
-
Result:Significantly reduced spheroid area of MCF7 cells compared with the untreated control after 8 and 12 days of treatment. Significantly reduced spheroid size of A375 cells after 4 days of culture.
-
Cell Line:MCF7, A375
-
Concentration:5 μM
-
Incubation Time:7 days
-
Result:Reduced the proportion of G2/M phase cells to 15.65% in MCF7 cells (vs. 26.25% untreated) and to 1.94% in A375 cells (vs. 5.44% untreated).
-
Cell Line:MCF7, A375
-
Concentration:5 μM
-
Incubation Time:7 days
-
Result:Significantly upregulated genes associated with G1/S transition and S-phase entry in MCF7 cells. Significantly downregulated key regulators of the G1/S transition and S-phase entry, including CCND1, CDK4, CDK6, and CCNE1, in A375 cells.\nInduced a notable increase in the expression of senescence-associated factors, including p21, p53, IGFBP3, and GDF15, in both MCF7 and A375 cells.\nSignificantly upregulated classical SASP components including IL-6 and IL-8 in MCF7 cells. Did not induce SASP factor expression and showed a trend toward reduced synthesis in A375 cells.
Chemical Information
-
CAS No. 1414873-26-9
-
Molecular Weight 435.44
-
Formula C25H20F3N3O
-
SMILES
FC(F)(C1=CC=C(C=C1)C2=CC(C3=CC=CC4=C3C=CC=C4)=NC(N5CCOCC5)=N2)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Senescence-associated β-galactosidase staining
Senescence-associated β-galactosidase staining detects β-galactosidase activity that is histochemically visible at pH 6. 0 in senescent cells, where X-gal cleavage produces an insoluble blue precipitate observable by bright-field microscopy. This activity reflects increased lysosomal β-galactosidase/lysosomal mass rather than a senescence-essential enzyme, because GLB1 depletion or genetic lysosomal β-galactosidase deficiency can abolish SA-β-gal staining while cells still undergo senescence. SA-β-gal was originally reported in senescent but not presenescent fibroblasts and keratinocytes, absent from quiescent fibroblasts and terminally differentiated keratinocytes, and increased with donor age in human skin samples. Because SA-β-gal can also appear in some non-senescent or tissue-specific contexts, interpretation should be paired with experimental controls and, when possible, independent senescence markers.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)